GO:0002829 negative regulation of type 2 immune response: Immune Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002829 describes any process that stops, prevents, or reduces the frequency, rate, or extent of a type 2 immune response, including negative regulation of Th2 responses.
• Key negative regulators include PAC1 (ADCYAP1R1), which constrains type 2 inflammation by promoting CGRP signaling in ILC2s, and metabolic checkpoints such as iron availability that control ILC2 effector function.
• Innate immune pathways such as cGAS-STING and MAVS are negatively regulated by SIRT2, SESN1, and TRIM13, indirectly shaping type 2 immunity.
• Viral factors can subvert negative regulation; for example, foot-and-mouth disease virus VP1 degrades YTHDF2 to modulate IRF3 activity.
• Dysregulation of this process is linked to asthma, allergy, and airway hyperreactivity, where uncontrolled type 2 inflammation drives pathology.
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect causal roles of negative regulators in type 2 immune responses.
Description
The type 2 immune response is a specialized branch of immunity characterized by the production of cytokines such as IL-4, IL-5, and IL-13, and the activation of effector cells including Th2 cells, ILC2s, eosinophils, and mast cells. While essential for host defense against helminths and for tissue repair, unrestrained type 2 immunity underlies allergic diseases such as asthma. GO:0002829, negative regulation of type 2 immune response, encompasses all molecular and cellular processes that restrain the initiation, intensity, or duration of this response. Understanding these checkpoints is critical for therapeutic intervention in allergy and asthma. Recent studies have identified diverse negative regulators, from neuropeptide receptors like PAC1 to metabolic sensors such as iron regulatory proteins, and innate immune modulators like SIRT2 and SESN1. This article synthesizes current knowledge on the mechanisms, key genes, and research methodologies for studying GO:0002829.
negative regulation of type 2 immune response At A Glance
| GO ID | GO:0002829 |
|---|---|
| GO term | negative regulation of type 2 immune response |
| Ontology | biological_process |
| Synonym | down regulation of type 2 immune response, down-regulation of type 2 immune response, downregulation of type 2 immune response, inhibition of type 2 immune response, negative regulation of Th2 immune response, negative regulation of T-helper 2 type immune response |
| Major function | Restrains the initiation, intensity, and duration of type 2 immune responses, including Th2 and ILC2 activation |
| Related processes | Regulation of cytokine production, ILC2 metabolism, neuroimmune interactions |
| Key regulators | PAC1, CGRP, iron metabolism, SIRT2, SESN1, TRIM13 |
| Disease relevance | Asthma, allergy, airway hyperreactivity, helminth infections |
What Is GO:0002829?
GO:0002829, negative regulation of type 2 immune response, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of a type 2 immune response. This includes inhibition of Th2 cell differentiation, suppression of ILC2 activation, and dampening of type 2 cytokine production. It is a biological process that ensures immune homeostasis and prevents excessive inflammation.
Why Is negative regulation of type 2 immune response Important in Cell Biology?
Negative regulation of type 2 immune response is essential for preventing allergic pathology and maintaining immune balance. Dysregulation leads to chronic inflammatory diseases such as asthma, where excessive type 2 cytokines drive airway hyperreactivity and remodeling. Understanding these regulatory mechanisms provides targets for therapeutic intervention and informs vaccine design.
• Prevents excessive type 2 inflammation that contributes to asthma and allergic rhinitis.
• Controls ILC2 metabolism and effector function via iron availability.
• Modulates neuroimmune circuits through PAC1-CGRP signaling.
• Influences host defense against helminths by balancing effector and regulatory arms.
• Impacts antiviral immunity through cGAS-STING and MAVS regulation.
• Provides therapeutic targets for allergy and asthma.
• Guides development of CRISPR models to study gene function.
• Relevant to understanding viral immune evasion, e.g., FMDV VP1.
• Links metabolic pathways to immune regulation.
• Essential for designing immunotherapies that avoid type 2 skewing.
What Happens During negative regulation of type 2 immune response?
Initiation of Negative Regulation
In simple terms: The body starts to put brakes on type 2 immunity.
Negative regulation begins when sensors detect excessive type 2 cytokines or activation signals. For example, PAC1 (ADCYAP1R1) on ILC2s promotes CGRP signaling, which constrains type 2 inflammation. Metabolic cues such as iron availability also initiate regulatory programs in ILC2s.
Suppression of Th2 and ILC2 Activation
In simple terms: The brakes are applied to immune cells that drive allergy.
PAC1 activation by CGRP reduces ILC2 proliferation and cytokine production. Iron deficiency impairs ILC2 effector function and airway hyperreactivity. These mechanisms dampen the type 2 response.
Innate Immune Checkpoints
In simple terms: Other immune pathways help keep type 2 responses in check.
SIRT2 deacetylates G3BP1 to negatively regulate the cGAS-STING pathway, while SESN1 negatively regulates STING1 to maintain innate immune homeostasis. TRIM13 targets MAVS for autophagic degradation, attenuating antiviral innate immunity. These checkpoints indirectly influence type 2 immunity.
Viral Subversion of Negative Regulation
In simple terms: Some viruses break the brakes to replicate better.
Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity, promoting viral replication. This illustrates how pathogens can subvert negative regulatory mechanisms.
Resolution and Homeostasis
In simple terms: The response is resolved and balance is restored.
MORC3 self-guarding enables virulence factor-triggered immunity, and m6A modification controls innate immune responses to infection by targeting type I interferons. These pathways contribute to restoring homeostasis after type 2 inflammation.
Key Genes Involved in GO:0002829 negative regulation of type 2 immune response
The following genes and proteins are key players in the negative regulation of type 2 immune response, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADCYAP1R1 (PAC1) | Promotes CGRP signaling to constrain type 2 inflammation in ILC2s | Target for asthma and allergy therapy |
| CGRP | Neuropeptide that suppresses ILC2 activation | Neuroimmune regulation |
| SIRT2 | Deacetylates G3BP1 to negatively regulate cGAS-STING | Innate immune checkpoint |
| SESN1 | Negatively regulates STING1 to maintain homeostasis | Innate immune regulation |
| TRIM13 | Targets MAVS for autophagic degradation | Antiviral innate immunity |
| YTHDF2 | m6A reader degraded by FMDV VP1 to regulate IRF3 | Viral immune evasion |
| MORC3 | Self-guarding enables virulence factor-triggered immunity | Host-pathogen interaction |
| IRF3 | Transcription factor regulated by YTHDF2 | Antiviral response |
| G3BP1 | Deacetylated by SIRT2 in cGAS-STING regulation | Stress granule and immune signaling |
| STING1 | Negatively regulated by SESN1 | Innate immune homeostasis |
| MAVS | Degraded by TRIM13 | Antiviral signaling |
| ILC2 | Innate lymphoid cells that drive type 2 immunity | Target of negative regulation |
| Th2 cells | Adaptive T helper cells producing IL-4, IL-5, IL-13 | Central to type 2 immunity |
| IL-4 | Type 2 cytokine | Biomarker of type 2 response |
| IL-5 | Type 2 cytokine | Eosinophil activation |
| IL-13 | Type 2 cytokine | Airway hyperreactivity |
| Iron | Metabolic regulator of ILC2 function | Metabolic control of type 2 immunity |
How Is negative regulation of type 2 immune response Regulated?
Negative regulation of type 2 immune response is controlled by multiple layers. Neuroimmune circuits via PAC1-CGRP suppress ILC2 activation. Metabolic cues such as iron availability modulate ILC2 metabolism and effector function. Innate immune checkpoints including SIRT2, SESN1, and TRIM13 regulate cGAS-STING and MAVS pathways, indirectly influencing type 2 immunity. Viral proteins like FMDV VP1 can subvert these brakes by degrading YTHDF2. Additionally, m6A modification controls innate immune responses by targeting type I interferons, and MORC3 self-guarding enables virulence factor-triggered immunity.
negative regulation of type 2 immune response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADCYAP1R1 (PAC1) | Asthma, airway hyperreactivity | KO mouse, ILC2-specific knockout |
| Iron metabolism genes | Asthma, airway hyperreactivity | Dietary iron modulation in mouse models |
| SIRT2 | Innate immune dysregulation | KO mouse, cGAS-STING reporter |
| SESN1 | Autoinflammation | KO mouse, STING1 reporter |
| TRIM13 | Antiviral immunity | KO chicken cells, MAVS degradation assay |
Asthma and Airway Hyperreactivity
Loss of negative regulation leads to excessive type 2 inflammation, driving airway hyperreactivity. PAC1 signaling constrains type 2 inflammation in ILC2s, and its dysfunction is associated with asthma. Iron deficiency impairs ILC2 function and airway hyperreactivity, linking metabolism to asthma pathogenesis.
Allergic Diseases
Unchecked Th2 responses underlie allergic rhinitis, atopic dermatitis, and food allergy. Negative regulators such as PAC1 and CGRP are potential therapeutic targets.
Viral Infections and Immune Evasion
Viruses like FMDV subvert negative regulation by degrading YTHDF2 to modulate IRF3, enhancing replication. Similarly, TRIM13 attenuates antiviral immunity by targeting MAVS, and SIRT2/SESN1 regulate STING to maintain homeostasis.
From negative regulation of type 2 immune response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PAC1 negatively regulate ILC2 activation? | PAC1 knockout mouse, ILC2-specific deletion |
| How does iron availability affect ILC2 function? | Iron-deficient diet mouse model |
| Does SIRT2 deacetylate G3BP1 to regulate STING? | SIRT2 KO cells, acetylation assays |
| Does SESN1 negatively regulate STING1? | SESN1 KO mouse, STING1 reporter |
| Does TRIM13 target MAVS for degradation? | TRIM13 overexpression in avian cells |
| How does FMDV VP1 degrade YTHDF2? | VP1 overexpression, autophagy inhibitors |
How to Study the negative regulation of type 2 immune response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Gene function loss | PAC1, SIRT2, SESN1 in immune cells |
| RNA-seq | Transcriptional changes | Type 2 cytokine gene expression |
| Flow cytometry | Immune cell populations | ILC2, Th2 quantification |
| ELISA | Cytokine levels | IL-4, IL-5, IL-13 measurement |
| Seahorse assay | Metabolic flux | ILC2 metabolism |
| Immunofluorescence | Protein localization | CGRP signaling |
| Autophagy flux assay | Autophagic degradation | YTHDF2 degradation by VP1 |
| Acetylation assay | Post-translational modifications | G3BP1 deacetylation by SIRT2 |
Genetic Knockout Models
CRISPR-Cas9 knockout of candidate genes such as PAC1 or SIRT2 in mice or cell lines allows assessment of their role in type 2 immune regulation.
Transcriptomic and Cytokine Profiling
RNA-seq and cytokine arrays measure type 2 cytokine production (IL-4, IL-5, IL-13) in response to negative regulators.
Metabolic Assays
Seahorse and iron quantification assess ILC2 metabolism and iron dependence.
Imaging and Flow Cytometry
Flow cytometry quantifies ILC2 and Th2 cell populations; immunofluorescence visualizes CGRP signaling.
How CRISPR Can Be Used to Study GO:0002829 negative regulation of type 2 immune response
Knockout
CRISPR knockout of negative regulators such as PAC1 or SIRT2 can reveal their suppressive roles in type 2 immunity. For example, PAC1 knockout exacerbates type 2 inflammation in ILC2s.
Point Mutation
Introducing point mutations in catalytic residues of SIRT2 or SESN1 can dissect their enzymatic functions in immune regulation.
Knock-in
Knock-in of tagged versions of TRIM13 or YTHDF2 allows tracking their degradation and interaction with MAVS or IRF3.
Overexpression
Overexpression of PAC1 or CGRP in ILC2s can enhance negative regulation and reduce airway hyperreactivity.
How EDITGENE Supports negative regulation of type 2 immune response Research
Researchers studying negative regulation of type 2 immune response-related genes often need to determine whether a candidate gene is causally involved in suppressing type 2 inflammation or is merely a bystander. EDITGENE provides CRISPR-based services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as library screening and bioinformatics support, to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of type 2 immune response research.
Frequently Asked Questions About negative regulation of type 2 immune response
What is negative regulation of type 2 immune response?
It is any process that stops, prevents, or reduces the frequency, rate, or extent of a type 2 immune response, as defined by GO:0002829.
What genes are involved in negative regulation of type 2 immune response?
Key genes include ADCYAP1R1 (PAC1), SIRT2, SESN1, TRIM13, YTHDF2, and MORC3, among others.
How does PAC1 regulate type 2 immunity?
PAC1 promotes CGRP signaling in ILC2s to constrain type 2 inflammation.
What is the role of iron in type 2 immune regulation?
Iron controls ILC2 metabolism and effector function, affecting airway hyperreactivity.
How do SIRT2 and SESN1 regulate innate immunity?
SIRT2 deacetylates G3BP1 to negatively regulate cGAS-STING, while SESN1 negatively regulates STING1.
What diseases are linked to dysregulation of this process?
Asthma, allergy, and airway hyperreactivity are associated with loss of negative regulation.
How can CRISPR be used to study this process?
CRISPR knockout, knock-in, and overexpression models allow functional dissection of candidate genes.
What methods measure type 2 immune responses?
Flow cytometry, ELISA, RNA-seq, and metabolic assays are commonly used.
Is there a connection to viral infections?
Yes, viruses like FMDV can subvert negative regulation by degrading YTHDF2.
What model organisms are used?
Mouse models, particularly for ILC2 and Th2 studies, are widely used.
Conclusion
Negative regulation of type 2 immune response (GO:0002829) is a critical biological process that prevents excessive type 2 inflammation and maintains immune homeostasis. Key regulators such as PAC1, SIRT2, SESN1, and TRIM13 provide promising targets for therapeutic intervention in asthma and allergic diseases. CRISPR-based models and advanced methodologies will continue to unravel the complex mechanisms underlying this regulation.
References
- 1. Liu H et al.. 2024. Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity for viral replication.. Autophagy 20(7):1597-1615 PMID: 38516932
- 2. Li Y et al.. 2023. SIRT2 negatively regulates the cGAS-STING pathway by deacetylating G3BP1.. EMBO Rep 24(12):e57500 PMID: 37870259
- 3. Xu L et al.. 2025. SESN1 negatively regulates STING1 to maintain innate immune homeostasis.. Autophagy 21(6):1245-1262 PMID: 39945079
- 4. Jin Y et al.. 2024. PAC1 constrains type 2 inflammation through promotion of CGRP signaling in ILC2s.. J Clin Invest 134(21) PMID: 39287985
- 5. Zhou P et al.. 2025. Avian TRIM13 attenuates antiviral innate immunity by targeting MAVS for autophagic degradation.. Autophagy 21(4):754-770 PMID: 39508267
- 6. Gaidt MM et al.. 2021. Self-guarding of MORC3 enables virulence factor-triggered immunity.. Nature 600(7887):138-142 PMID: 34759314
- 7. Winkler R et al.. 2019. m(6)A modification controls the innate immune response to infection by targeting type I interferons.. Nat Immunol 20(2):173-182 PMID: 30559377
- 8. Hurrell BP et al.. 2024. Iron controls the development of airway hyperreactivity by regulating ILC2 metabolism and effector function.. Sci Transl Med 16(746):eadk4728 PMID: 38718131
